[go: up one dir, main page]

About: Darexaban

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Darexaban (YM150) is a direct inhibitor of factor Xa created by Astellas Pharma. It is an experimental drug that acts as an anticoagulant and antithrombotic to prevent venous thromboembolism after a major orthopaedic surgery, stroke in patients with atrial fibrillation and possibly ischemic events in acute coronary syndrome. It is used in form of the maleate. The development of darexaban was discontinued in September 2011.

Property Value
dbo:abstract
  • داركزبان (YM150) هو مانعٌ مباشر للعامل العاشر وقد تمّ انشاؤه من قبل شركة أستيلّاس. وهو الدّواء التّجريبيّ الذي يعمل كمضادّ للتّجلط لمنع الجلطات الدمويّة الوريديّة بعد جراحة العظام الرئيسية، والسكتة الدماغية في المرضى الذين يعانون من الرّجفان الأذينيّ ونقص الأكسجين في الدّم الذي قد يترافق مع متلازمة الشّريان التّاجي الحادّة. يستخدم الداركزبان على شكل حمض الماليك. وقد توقّف تطويره في سبتمبر عام 2011م. (ar)
  • Darexaban (YM150) is a direct inhibitor of factor Xa created by Astellas Pharma. It is an experimental drug that acts as an anticoagulant and antithrombotic to prevent venous thromboembolism after a major orthopaedic surgery, stroke in patients with atrial fibrillation and possibly ischemic events in acute coronary syndrome. It is used in form of the maleate. The development of darexaban was discontinued in September 2011. (en)
  • Darexaban, già noto con la sigla YM150, commercializzato come sale darexaban maleato, è un composto anticoagulante ed antitrombotico, un inibitore diretto del fattore Xa. Il farmaco è stato sviluppato dalla società farmaceutica Astellas Pharma. Il farmaco è oggetto di studio per la prevenzione del tromboembolismo venoso dopo intervento ortopedico sugli arti inferiori, nella prevenzione dell'ictus cerebrale in soggetti affetti da fibrillazione atriale e degli eventi ischemici nella sindrome coronarica acuta. (it)
dbo:alternativeName
  • YM150 (en)
dbo:iupacName
  • N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide (en)
dbo:thumbnail
dbo:wikiPageID
  • 35019978 (xsd:integer)
dbo:wikiPageLength
  • 9666 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1023482814 (xsd:integer)
dbo:wikiPageWikiLink
dbp:imagefile
  • Darexaban.svg (en)
dbp:imagesize
  • 200 (xsd:integer)
dbp:othernames
  • YM150 (en)
dbp:pin
  • N-[2-Hydroxy-6-phenyl]-4-benzamide (en)
dbp:wikiPageUsesTemplate
dct:subject
gold:hypernym
rdf:type
rdfs:comment
  • داركزبان (YM150) هو مانعٌ مباشر للعامل العاشر وقد تمّ انشاؤه من قبل شركة أستيلّاس. وهو الدّواء التّجريبيّ الذي يعمل كمضادّ للتّجلط لمنع الجلطات الدمويّة الوريديّة بعد جراحة العظام الرئيسية، والسكتة الدماغية في المرضى الذين يعانون من الرّجفان الأذينيّ ونقص الأكسجين في الدّم الذي قد يترافق مع متلازمة الشّريان التّاجي الحادّة. يستخدم الداركزبان على شكل حمض الماليك. وقد توقّف تطويره في سبتمبر عام 2011م. (ar)
  • Darexaban (YM150) is a direct inhibitor of factor Xa created by Astellas Pharma. It is an experimental drug that acts as an anticoagulant and antithrombotic to prevent venous thromboembolism after a major orthopaedic surgery, stroke in patients with atrial fibrillation and possibly ischemic events in acute coronary syndrome. It is used in form of the maleate. The development of darexaban was discontinued in September 2011. (en)
  • Darexaban, già noto con la sigla YM150, commercializzato come sale darexaban maleato, è un composto anticoagulante ed antitrombotico, un inibitore diretto del fattore Xa. Il farmaco è stato sviluppato dalla società farmaceutica Astellas Pharma. Il farmaco è oggetto di studio per la prevenzione del tromboembolismo venoso dopo intervento ortopedico sugli arti inferiori, nella prevenzione dell'ictus cerebrale in soggetti affetti da fibrillazione atriale e degli eventi ischemici nella sindrome coronarica acuta. (it)
rdfs:label
  • داركزبان (ar)
  • Darexaban (en)
  • Darexaban (it)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License